Urovant Sciences® Named 17th on the List of Fortune® Best Workplaces in BioPharma™ (2022)
Urovant Sciences, Inc. receives Fortune and Great Place to Work Best Workplaces in Biopharma (2022) recognition.
Follows Urovant’s Best Place to Work recognition by the Orange County Business Journal for the second year in a row, along with becoming a Great Places to Work-Certified™ company earlier this year.
The Best Workplaces in BioPharma award is based on analysis of survey responses from more than 36,000 employees from Great Place to Work-Certified companies in the biopharma industry.
Urovant is a growing leader in the field of urology, employing more than 300 employees in the United States and Europe, and recently launched its first commercial product for Overactive Bladder (OAB) in April 2021.
IRVINE, Calif. & BASEL, Switzerland – September 7, 2022 – Great Place to Work and Fortune magazine have named Urovant Sciences as one of the Best Workplaces in BioPharma. This is Urovant’s first time being named to this prestigious list, this year coming in at 17th place. Earning a spot means that Urovant is one of the best companies to work for in the country.
The Best Workplaces in BioPharma award is based on analysis of survey responses from more than 36,000 employees from Great Place to Work-Certified™ companies in the biopharma industry. In that survey, 89% of Urovant’s employees said Urovant is a great place to work. This number is 32% higher than the average U.S. company.
“It’s an honor to be recognized by Fortune and Great Place to Work,” said James Robinson, CEO of Urovant Sciences. “We like to say we are Powered by People and Possibilities. Developing a diverse, welcoming, and action-oriented culture has been and continues to be a priority at Urovant. This allows us to advance patient care through our culture with values of integrity and compassion, bold innovation through inclusion, and achievement through collaboration.”
The Fortune Best Workplaces in BioPharma list is highly competitive. Great Place to Work, the global authority on workplace culture, selected the list using rigorous analytics and confidential employee feedback. Companies were considered if they are a Great Place to Work-Certified organization.
Great Place to Work is the only company culture award in America that selects winners based on how fairly employees are treated. Companies are assessed on how well they are creating a great employee experience that cuts across race, gender, age, disability status, or any aspect of who employees are or what their role is.
“It is our honor to spotlight the Best Workplaces in BioPharma,” says Michael C. Bush, CEO of Great Place to Work. “We applaud their commitment to inclusive, high-trust cultures.”
In addition to becoming a certified Great Place to Work earlier this year, Urovant was named one of the Best Places to Work for the second year in a row by the Orange County Business Journal.
About Urovant Sciences
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for areas of unmet need, with a dedicated focus in urology. The Company’s lead product, GEMTESA®(vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. GEMTESA was approved by the U.S. FDA in December 2020 and launched in the U.S. in April 2021. GEMTESA is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia. The Company’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy. Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., intends to bring innovation to patients in need in urology and other areas of unmet need. Learn more about Urovant at www.Urovant.com or follow on Twitter, Linked In or Instagram.
About Sumitovant Biopharma
Sumitovant is a technology-driven biopharmaceutical company accelerating development of new potential therapies for patients with high unmet medical need. Through our subsidiary portfolio and use of embedded computational technology platforms to generate business and scientific insights, Sumitovant has supported development of FDA-approved products and advanced a promising pipeline of early- through late-stage investigational assets for other serious conditions. Sumitovant’s subsidiary portfolio includes wholly-owned Enzyvant, Urovant, Spirovant, and Altavant, and one majority-owned subsidiary that is publicly listed: Myovant (NYSE: MYOV). Sumitomo Pharma is Sumitovant’s parent company. For more information, please visit www.sumitovant.com.
About the Best Workplaces in BioPharma™
Great Place to Work® selected the Best Workplaces in BioPharma™ by gathering and analyzing confidential survey responses from more than 36,000 employees at Great Place to Work-Certified™ organizations in the biopharma industry. Company rankings are derived from 60 employee experience questions within the Great Place to Work® Trust Index™ survey. Great Place to Work determines its lists using its proprietary For All™ methodology to evaluate and certify thousands of organizations in America’s largest ongoing annual workforce study, based on over 1 million survey responses and data from companies representing more than 6.1 million employees, this year alone.
About Great Place to Work®
Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees worldwide and used those deep insights to define what makes a great workplace: trust. Their employee survey platform empowers leaders with the feedback, real-time reporting and insights they need to make data-driven people decisions. Everything they do is driven by the mission to build a better world by helping every organization become a great place to work For All™.
About Overactive Bladder
Overactive bladder (OAB) is a clinical condition that occurs when the bladder muscle contracts involuntarily. Symptoms may include urinary urgency (the sudden urge to urinate that is difficult to control), urgency incontinence (unintentional loss of urine immediately after an urgent need to urinate), frequent urination (usually eight or more times in 24 hours), and nocturia (waking up more than two times in the night to urinate).1
Approximately 30 million Americans suffer from bothersome symptoms of OAB, which can have a significant impairment on a patient’s day-to-day activities.1, 2
GEMTESA is a prescription medicine for adults used to treat the following symptoms due to a condition called overactive bladder:
- urge urinary incontinence: a strong need to urinate with leaking or wetting accidents
- urgency: the need to urinate right away
- frequency: urinating often
It is not known if GEMTESA is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Do not take GEMTESA if you are allergic to vibegron or any of the ingredients in GEMTESA.
Before you take GEMTESA, tell your doctor about all your medical conditions, including if you have liver problems; have kidney problems; have trouble emptying your bladder or you have a weak urine stream; take medicines that contain digoxin; are pregnant or plan to become pregnant (it is not known if GEMTESA will harm your unborn baby; talk to your doctor if you are pregnant or plan to become pregnant); are breastfeeding or plan to breastfeed (it is not known if GEMTESA passes into your breast milk; talk to your doctor about the best way to feed your baby if you take GEMTESA).
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
What are the possible side effects of GEMTESA?
GEMTESA may cause serious side effects, including the inability to empty your bladder (urinary retention). GEMTESA may increase your chances of not being able to empty your bladder, especially if you have bladder outlet obstruction or take other medicines for treatment of overactive bladder. Tell your doctor right away if you are unable to empty your bladder. The most common side effects of GEMTESA include headache, urinary tract infection, nasal congestion, sore throat or runny nose, diarrhea, nausea, and upper respiratory tract infection. These are not all the possible side effects of GEMTESA. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please click here for full Product Information for GEMTESA.
- Reynolds, W. S., Fowke, J., & Dmochowski, R. (2016). The Burden of Overactive Bladder on US Public Health. Current bladder dysfunction reports, 11(1), 8–13. https://doi.org/10.1007/s11884-016-0344-9
- Coyne, K. S., Sexton, C. C., Vats, V., Thompson, C., Kopp, Z. S., & Milsom, I. (2011). National community prevalence of overactive bladder in the United States stratified by sex and age. Urology, 77(5), 1081–1087.
UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo and Powered by People and Possibilities are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries. All other trademarks are the property of their respective owners. © 2022 Urovant Sciences. All rights reserved.
From Fortune. ©2022 Fortune Media IP Limited. All rights reserved. Used under license.
Alana Darden Powell
Vice President, Corporate Communications
VP, Head of Corporate Communications
Source: Urovant Sciences, Inc.